Keel Point’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$230K Sell
410
-218
-35% -$140K 0.02% 410
2025
Q4
$425K Sell
628
-50
-7% -$34.1K 0.03% 334
2025
Q3
$433K Buy
678
+65
+11% +$39.5K 0.03% 330
2025
Q2
$329K Sell
613
-20
-3% -$9.56K 0.02% 380
2025
Q1
$266K Buy
+633
New +$275K 0.02% 374
2024
Q4
Sell
-594
Closed -$300K 457
2024
Q3
$300K Buy
594
+18
+3% +$8.74K 0.03% 327
2024
Q2
$281K Buy
576
+49
+9% +$24.6K 0.03% 330
2024
Q1
$285K Buy
527
+49
+10% +$26.8K 0.03% 293
2023
Q4
$265K Sell
478
-12
-2% -$5.63K 0.03% 279
2023
Q3
$214K Sell
490
-12
-2% -$5.98K 0.03% 291
2023
Q2
$252K Buy
502
+68
+16% +$32.6K 0.03% 269
2023
Q1
$217K Buy
+434
New +$208K 0.03% 281
2021
Q2
Sell
-470
Closed -$230K 293
2021
Q1
$230K Buy
+470
New +$235K 0.02% 241

Other funds holding IDXX

Keel Point's IDXX Position: Q1 2026 in Review

Keel Point reduced its Idexx Laboratories (IDXX) stake by 35% in Q1 2026, selling an estimated $140K and leaving 410 shares worth $230K. The position accounts for 0.02% of the portfolio, ranked #410.

Keel Point first reported a position in IDXX in Q1 2021 and has held it in 13 quarters since. The position peaked at $433K in Q3 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Keel Point held 410 shares of Idexx Laboratories worth $230K as of Q1 2026.
  • Keel Point sold 218 Idexx Laboratories shares in Q1 2026, an estimated $140K.
  • Idexx Laboratories made up 0.02% of Keel Point's portfolio in Q1 2026, its #410 holding.
  • Keel Point first reported a position in Idexx Laboratories in Q1 2021 and has held it in 13 quarters since.
  • Keel Point's Idexx Laboratories position peaked at $433K in Q3 2025.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Keel Point's 13F filing for Q1 2026, filed 1 Jun 2026.